
Expanded Access for CC-4047
Multiple MyelomaThis is an expanded access program (EAP) for eligible participants designed to provide access to CC-4047.

Individual Patient Compassionate Use of Fedratinib
MyelofibrosisThis is an expanded access program (EAP) for eligible participants designed to provide access to fedratinib. Expanded access is only available in markets where fedratinib is not yet approved.

Fecal Microbiota Transplantation (FMT): PRIM-DJ2727
Recurrent Clostridium Difficile InfectionMultidrug-resistant Klebsiella Pneumoniae Urinary Tract InfectionThe Fecal Microbiota Transplantation (FMT) product PRIM-DJ2727 is prepared from human stool from a healthy, screened donor. Requestors will contact the study team about the product (PRIM-DJ2727) by email, visit, or phone call. A screening list for donors will be provided to make sure that the list fits the requestor's requirements. A basic fee will be requested to recover the cost of making the product. After an agreement is made, a contract will be signed between the 2 parties. A week before the treatment, requestors will contact the study team for possible FMT product delivery. Delivery method will be confirmed for delivery by personnel (within 10 minutes driving distance) or by using FedEx services. Each delivered product will have an approved delivery form signed and dated by both the person who prepared the delivery and the person who received the package.

Expanded Access to Provide Selitrectinib for the Treatment of Cancers With a NTRK Gene Fusion
Solid Tumors Harboring NTRK FusionSelitrectinib expanded access is for minor and adult patients with cancer having a change in a particular gene (NTRK1, NTRK2, or NTRK3 gene fusion). The patients are ineligible for an ongoing selitrectinib clinical trial or have other considerations that prevent access to selitrectinib through an existing clinical trial. Expanded access is intended to treat individual patients with different types of cancers with a NTRK gene fusion, including blood cancers, who have previously received tropomyosin receptor kinase (TRK) inhibitor therapy.

cliniMACs HUD for T Cell Depletion
x Linked Combined ImmunodeficiencyThis protocol is designed to enable access to related or unrelated CD34 cells manufactured using the CliniMACS (Miltenyi) under the HUD designation for patients needing T cell depleted allogeneic grafts for hematopoietic stem cell transplant (HSCT). This will include patients with inherited immunodeficiency disorders as well as patients with malignancies, bone marrow failure, and other rare diseases amenable to HSCT. Finally, patients with poor graft function and Graft Versus Host Disease(GVHD) after a previous HSCT may require a boost of T-cell depleted donor Peripheral Blood Stem Cell (PBSCs) or bone marrow cells that are CD34 selected using the CliniMACS device ENROLLMENT BY INVITATION ONLY

Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR)
TTR-mediated AmyloidosisAmyloidosis8 moreThe purpose of this study is to provide expanded access of patisiran to patients with hereditary transthyretin-mediated amyloidosis (hATTR).

A Clinical Study of CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies...
Relapsed and Refractory Hematological MalignanciesThis project is intended to provide CAR-T cell therapy products for patients with severely life-threatening relapsed and refractory hematological malignancies. These patients have been previously treated sufficiently, currently have no other treatment methods available, and do not meet the inclusion criteria of other clinical trial projects in the process of subject recruitment or meet their exclusion criteria. This project is designed to meet the urgent clinical needs of individual patients.

Expanded Access for Treatment Use of PLX-PAD in Critical Limb Ischemia (CLI)
Critical Limb Ischemia (CLI)This is an Expanded Access program (EAP), sponsored by WideTrial for the treatment of critical limb ischemia (CLI). Widetrial, an Expanded Access specialist, has arranged to supply participating sites with PLX-PAD for CLI patients who cannot participate in the ongoing research trial and who seek exploratory treatment options. This program includes FDA-authorized cost recovery, meaning payment is required to cover a portion of the costs of delivering product and complying with regulatory obligations.

Expanded Access Use of Itacitinib to Treat a Single Patient With Aplastic Anemia
Aplastic AnemiaExpanded Access Use of Itacitinib to Treat a Single Patient With Aplastic Anemia

Expanded Access of Pemigatinib to Treat a Single Patient With Metastatic Pancreatic Cancer
Expanded access of Pemigatinib to treat a single patient with metastatic pancreatic cancer.